

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



2023

1/2





® PD-1

1H23 5.56

3 ES-SCLC

ES-SCLC

PD-1

3 ES-SCLC

MAA

EMA

9 ESCC



Argesun®



®

#

®

#



®

#



®

#



®



®



®



®

HER2

RT002

#

Tenapanor

#

FS-1502 HER2-ADC #

13

FCN-159 MEK

ET-26

SAB Scientific Advisory Board




CDE 2021 7





DRG/DIP

战略合作伙伴












Gland





MSCI-ESG


A





-


1



2,3



3



SCLC

PD-1



PD-1



nature
medicine

IAAMA
Journal of the American Medical Association

BJC
British Journal of Cancer



(ASTCT)

r/r LBCL

2023 6 r/r LBCL

CAR-T

B LBCL
1.3

LBCL NHL 45.8%

NHL LBCL 4

ZUMA-1

RWS

ZUMA-7

bORR

bCR

OS

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T

/

B

Tecartus




2020 7

FDA

r/r ALL

/


MCL







1


12









1



2,3



3



6,448 * 9

JCI

1H23

“ ”



600

2017 11
60%

9.09



1,750

2022

21.45

1.11

800

87.41%

900


2022 1

70%



*

2023 6



		2023		2023	
2,254	14.71%			630	17.27%
C		2023			2023
	177	15.86%			



		®		
		®		
		®		
		®		
		®★		

		®★		
		®★		
		®★		
		T ®★		
		®		
		®		

		®★		
		®★		
				
		®★		
		mRNA ®★		
				

1/2

			/			IND	1	2	3	NDA
HLX10 ¹	+		PD-1	/	III 2022 11					
					2022 11 2022 FDA/EC 2023 1					
	+	+	PD-1		III 2023 1 2022 5					
	+		PD-1+VEGF		2022 1					
	+HLX07		PD-1+EGFR							
	+HLX07 +		PD-1+EGFR +VEGF							
HLX07		EGFR								
HLX22										
HLX11		2	HER2		III 2022					
HLX05		3	EGFR							
HLX02		4	HER2		FDA 2020					



1/2

		I			IND	1	2	3	NDA
FCN-437c		CDK4/6	1L						
			2L						
SAF-189		ALK/ROS1	ALK+		2022 1 NMPA III				
			ROS1+						
HLX-208	-	BRAF	Erdheim-Chester ECD LCH		2023 4 LCH ECD NMPA				
		BRAF+PD-1	BRAF V600E BRAF V600						
FCN-159		MEK	I		2023 7 NMPA			II	
					2023 4 NMPA		2022 5 NMPA		
YP01001		VEGFR			NMPA				
FCN-338		BCL-2			NMPA				
			B						
FH-2001		FGFR/PD-L1							
ORIN1001		IRE1							

2/2

		/			IND	1	2	3	NDA
		TPO-R	ITP						
	Tenapanor	NHE 3	(ESRD-HD)						
		P-CAB							
	Tenapanor	NHE 3	(IBS-C)						
	PA-824	-	XDR-TB / MDR-TB		Pretomanid*				
	Opicapone	COMT			Ongentys*				
	Fortacin	-			*				
	ET-26	-			2023 10	III			
	FCN-159	MEK							
	ORIN1001	IRE1							
	FCN-016	ROCK			2023 1	NMPA			
	SZEY-2108	-	CRE		2023 6	NMPA			

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.



www.fosunpharma.com